ArticleGenome medicine2021
Molecular profiling of advanced malignancies guides first-line N-of-1 treatments in the I-PREDICT treatment-naïve study.
Article in Genome medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 63 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
An Open Label Navigational Investigation of Molecular Profile-Related Evidence Determining Individualized Cancer Therapy for Patients With Incurable Malignancies and Poor Prognosis
STudy of Real-world Individualized Precision-oncology
Who cites it
63 citing papers in PubMed, 85 citations in OpenAlex.
- Article
- A tumor profiling resource for ovarian cancer: insights into chemotherapy-driven heterogeneity and personalized treatment strategy.Nature communications · 2026Article
- SYNTHESIS-Breast: A prospective early-phase trial of a genetic-interaction- focused computational algorithm in advanced metastatic breast cancer.Research square · 2026Article
- Further Promise and Potential for Precision Medicine in Oncology.Journal of medical Internet research · 2026Article
- Discovery of predictive biomarkers for cancer therapy through computational approaches.Nature reviews. Clinical oncology · 2026Review
- Investigation of Profile-Related Evidence Determining Individualized Cancer Therapy (I-PREDICT) N-of-1 Precision Oncology Study: Molecular Profiling to Match Individually Dosed, Personalized Drug Combinations.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2026Observational
- Integrating Genomics, Radiomics, and Pathomics in Oncology: A Scoping Review and a Framework for AI-Enabled Surgomics.Bioengineering (Basel, Switzerland) · 2026Review
- Integration of Whole-Genome Sequencing Analysis with Unique Patient-Derived Models Reveals Clinically Relevant Drug Targets in TFCP2 Fusion-Defined Rhabdomyosarcoma.Molecular cancer therapeutics · 2025Article
- Cracking the resistance code: The molecular reclassification of cancer and precision therapy strategies.Seminars in cancer biology · 2025Review
- Gene- and immune-targeted therapy combinations using dual-matched biomarkers for patient selection.NPJ precision oncology · 2025Article
- Tumour-agnostic kinase inhibitors.Nature reviews. Drug discovery · 2025Review
- PersonalizedJCO precision oncology · 2025Observational
- Worldwide Innovative Network (WIN) Consortium in Personalized Cancer Medicine: Bringing next-generation precision oncology to patients.Oncotarget · 2025Article
- Impact of travel costs on disparities in precision oncology clinical trials.ESMO real world data and digital oncology · 2025Article
- New systemic treatment paradigms in advanced biliary tract cancer and variations in patient access across Europe.The Lancet regional health. Europe · 2025Review
- Article
- Editorial: Clinical implementation of precision oncology data to direct individualized and immunotherapy-based treatment strategies.Frontiers in immunology · 2025Article
- Tumor necrosis factor superfamily signaling: life and death in cancer.Cancer metastasis reviews · 2024Review
- Successful Targeting of SomaticJournal of immunotherapy and precision oncology · 2024Article
- Therapeutic vulnerabilities and pan-cancer landscape of BRAF class III mutations in epithelial solid tumors.BJC reports · 2024Article
3 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors at 5 institutions in 1 country.
Funding
Abstract
backgroundMalignancies are molecularly complex and become more resistant with each line of therapy. We hypothesized that offering matched, individualized combination therapies to patients with treatment-naïve, advanced cancers would be feasible and efficacious. Patients with newly diagnosed unresectable/metastatic, poor-prognosis cancers were enrolled in a cross-institutional prospective study.
methodsA total of 145 patients were included in the study. Genomic profiling (tissue and/or circulating tumor DNA) was performed in all patients, and PD-L1 immunohistochemistry, tumor mutational burden, and microsatellite status assessment were performed in a subset of patients. We evaluated safety and outcomes: disease-control rate (stable disease for ≥ 6 months or partial or complete response), progression-free survival (PFS), and overall survival (OS).
resultsSeventy-six of 145 patients (52%) were treated, most commonly for non-colorectal gastrointestinal cancers, carcinomas of unknown primary, and hepatobiliary malignancies (53% women; median age, 63 years). The median number of deleterious genomic alterations per patient was 5 (range, 0-15). Fifty-four treated patients (71%) received ≥ 1 molecularly matched therapy, demonstrating the feasibility of administering molecularly matched therapy. The Matching Score, which reflects the percentage of targeted alterations, correlated linearly with progression-free survival (R
conclusionsPersonalized combination therapies targeting a majority of a patient's molecular alterations have antitumor activity as first-line treatment. These findings underscore the feasibility and importance of using tailored N-of-1 combination therapies early in the course of lethal malignancies.
trial registrationI-PREDICT ( NCT02534675 ) was registered on August 25, 2015.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.